Treatment before surgery for mid-high rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding two newer drugs to standard chemotherapy before surgery can shrink rectal tumors more effectively. It is for patients whose tumors are not too low in the rectum and have certain genetic markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has not spread to other parts of the body.
- Your tumor is located 6 to 15 cm from the anus (or more than 4 cm from the anal ring).
- Your cancer is a type called pMMR or MSS (your doctor can check this).
- You have not had any prior treatment for rectal cancer, such as surgery, radiation, or chemotherapy.
- You are healthy enough to have surgery and can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
This trial tests a combination of chemotherapy plus two newer medicines (suvemcitug and enlonstobart) before surgery for middle rectal cancer. The goal is to shrink the tumor and avoid radiation therapy, which may spare some side effects.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.